trial

Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.

NCTId NCT03510741
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 64 (actual)
Sponsored by Pakistan Institute of Living and Learning
Primary completion 2020-12-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
64 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Quadruple
Start
2019-01-01
Primary completion
2020-12-30
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Sodium BenzoateN-acetylcysteineSodium Benzoate Plus N-Acetylcysteine

Sponsors

Pakistan Institute of Living and LearningLead Sponsor

Investigators

1
Prof Imran B Chaudhry, MDPrincipal Investigator

Sites

5 total
Quetta, PakistanRawalpindi, PakistanKarachi, PakistanKarachi, PakistanKarachi, Pakistan

Linked catalysts

1
Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schi — primary completion2020-12-30

Facts & assertions

4 sourced
Enrollment
64
Phase
PHASE2
Primary Completion Date
2020-12-30
Status
COMPLETED
relationships
The graph out of here
drug
Sodium Benzoate
drug
N-acetylcysteine
drug
Sodium Benzoate Plus N-Acetylcysteine
drug
lead_sponsor
Pakistan Institute of Living and Learning
company
indication
Schizophreniform Disorders
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Prof Imran B Chaudhry, MD
person